The latest conversation in the battle against obesity is shifting gears, focusing on the importance of what type of weight is being lost with new anti-obesity medications. Experts are cautioning that, while fat loss is beneficial, the concurrent loss of muscle mass can be a disadvantage, potentially leading to frailty in patients achieving leaner bodies. In a Harvard Gazette interview, Dr. Fatima Cody Stanford from Harvard Medical School underscored the need for more comprehensive data on body composition changes, not just overall weight loss.
Clinicians are eager to see pharmaceutical companies to begin including body composition measurements in their studies, a call to action backed by recent research and expert opinion pieces, such as the one penned by Stanford and colleagues in JAMA Internal Medicine. Stanford, who has consulted for drugmaker Novo Nordisk, highlighted that it's not just about shedding pounds. "When I talk to patients about losing weight, I tell them I want them to lose weight and gain health. But weight loss doesn't mean gaining health if you're unable to get up out of your seat and chase after your grandkids," Stanford told the Harvard Gazette.
Current prescription criteria for GLP-1 anti-obesity medications are rooted mainly in body mass index (BMI) measurements. However, Stanford posed concerns about focusing solely on BMI rather than considering other health metrics like cholesterol levels, liver function tests, and blood pressure. Such an approach can vary the health status of individuals with the same BMI, potentially leading to misguided treatment plans.
While the effectiveness of these drugs isn't in question, the potential muscle mass loss they may cause, particularly in older adults, is a risk that needs attention. "The extensive studies, done by Novo Nordisk, Eli Lilly, or other companies — with 17,000, 20,000 people — don't look at the key metrics about body composition even though we've known for some time that with metabolic and bariatric surgery we need to pay attention to muscle loss in patients," Stanford explained in a Harvard Gazette interview.
Amid challenges like medication shortages and cautionary tales, healthcare professionals like Stanford are refining approaches to mitigate such issues as improper dosing. Stanford revealed that she has never encountered severe complications, such as hospitalization for stomach paralysis, in over 3,000 cases where she has prescribed these medications. However, the public still shares anecdotal evidence of adverse events potentially due to improper use. "A lot of the negative stories we’re hearing reflect people not understanding how to use these medications," Stanford pointed out.
The conversation around these cutting-edge treatments is evolving, as the demand for them rises in the ongoing global struggle against obesity. With new players expected to join the market and pharmaceutical juggernauts like Novo Nordisk investing heavily to improve their supply chains, it's clear the landscape is changing rapidly. But as the fight against obesity scales up, it is ever more critical that weight loss treatments balance efficacy with safeguarding patients' overall health and functionality.
